AKBA · Akebia Therapeutics, Inc.
$0.89
-0.06 (-6.49%)
At close · Aug 7
Market Cap
$264.47M
Shares
277.11M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$236.2M
+47.5%
FY2025
Net Income
-$5.3M
+92.4%
FY2025
Gross Margin
83.29%
+22.7pp
FY2025
Operating Margin
9.95%
+41.5pp
FY2025
Diluted EPS
-$0.02
+93.9%
FY2025
Operating Cash Flow
$67.99M
+267.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $219.06M | $236.2M | $160.18M | $194.62M | $292.48M | $211.65M | $294.64M | $335M | $207.74M | $181.23M | $1.54M | $0 | $0 | — | — | |
| $648K | — | — | — | — | — | — | — | — | — | — | $510K | $206K | -$704K | -$1.64M | |
| $44.63M | $39.46M | $63.18M | $74.15M | $85.57M | $150.67M | $296.48M | $145.34M | $7.77M | — | — | — | — | — | — | |
| $174.43M | $196.73M | $97M | $120.47M | $206.92M | $60.98M | -$1.83M | $189.67M | $199.97M | — | — | — | — | — | — | |
| — | 83.29% | 60.56% | 61.9% | 70.74% | 28.81% | -0.62% | 56.62% | 96.26% | — | — | — | — | — | — | |
| $70.46M | $62.36M | $37.65M | $63.08M | $129.99M | $147.85M | $218.49M | $322.97M | $291.01M | $230.89M | $115.79M | $43.02M | $23.26M | $8.9M | $5.63M | |
| $39.51M | — | — | — | — | — | — | — | — | $27.01M | $22.21M | $18.5M | $14.68M | $7.03M | $2.89M | |
| $113.79M | $107.48M | $106.55M | $100.23M | $138.6M | $174.14M | $154.1M | $149.46M | $87.06M | $27.01M | $22.21M | — | — | — | — | |
| — | $0 | $36.04M | $36.04M | $36.04M | $36.04M | $32.62M | $36.4M | $1.52M | — | — | — | — | — | — | |
| — | — | — | — | $1.65M | $1.93M | $2.08M | $2.25M | $899K | $617K | $296K | $96K | $49K | — | — | |
| — | $0 | $58K | $181K | $15.93M | $0 | $0 | — | — | — | — | — | — | — | — | |
| $189.55M | $173.24M | $147.48M | $166.73M | $287.7M | $325.48M | $375.99M | $475.95M | $378.14M | $257.9M | $138M | $61.51M | $37.94M | $15.93M | $8.52M | |
| -$15.13M | $23.5M | -$50.47M | -$46.26M | -$80.78M | -$264.5M | -$377.83M | -$286.29M | -$178.16M | -$76.67M | -$136.46M | -$61.51M | -$37.94M | -$15.93M | -$8.52M | |
| — | 9.95% | -31.51% | -23.77% | -27.62% | -124.97% | -128.23% | -85.46% | -85.76% | -42.31% | -8889.9% | — | — | — | — | |
| — | — | — | — | -$79.13M | -$262.58M | -$375.75M | -$284.04M | -$177.26M | -$76.06M | -$136.16M | -$61.42M | -$37.89M | — | — | |
| $2.06M | — | — | — | — | — | — | — | — | — | $901K | $510K | $206K | — | — | |
| -$131K | $58K | $94K | $887K | $3.15M | $2.41M | $1.86M | -$794K | $81K | $204K | -$188K | $287K | $700K | — | — | |
| -$27.85M | -$3.72M | -$69.41M | -$51.93M | -$94.23M | -$282.02M | -$384.84M | -$286.29M | -$171.93M | -$73.67M | -$135.75M | — | — | — | — | |
| $1.82M | $1.62M | $0 | $0 | $0 | $0 | $0 | -$6.63M | -$28.34M | — | — | — | — | — | — | |
| -$29.62M | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$282M | -$384.84M | -$279.66M | -$143.59M | -$73.67M | -$135.75M | -$60.72M | -$37.03M | -$13.17M | -$8.2M | |
| — | -2.24% | -43.33% | -26.67% | -32.21% | -133.24% | -130.61% | -83.48% | -69.12% | -40.65% | -8843.45% | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$135.75M | -$60.72M | -$123.93M | -$69.05M | -$11.52M | |
| -$29.67M | -$5.35M | -$69.41M | -$51.93M | -$94.23M | -$282.03M | -$384.83M | -$279.4M | -$143.41M | -$74.07M | -$135.79M | -$60.95M | -$37.09M | -$13.17M | -$8.2M | |
| USD/shares | — | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | -$2.78 | -$2.36 | — | — | — | — | — | — | — |
| USD/shares | — | -$0.02 | -$0.33 | -$0.28 | -$0.52 | -$1.70 | -$2.78 | -$2.36 | — | — | — | — | — | — | — |
| shares | — | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M | 138.46M | 118.4M | 58.04M | 43.5M | 37.72M | 26.47M | 15.41M | 544K | 414.11K |
| shares | — | 257.16M | 210.95M | 187.47M | 182.78M | 165.95M | 138.46M | 118.4M | 58.04M | 43.5M | 37.72M | 26.47M | 15.41M | 544K | 414.11K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.72×
Peer median 1.95×
EV/EBIT
—
Peer median 23.93×
P/E (TTM)
—
Peer median 15.70×
Peer medians compare against the 54 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $236,196,000 | $160,180,000 | $194,623,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $227,332,000 | $152,180,000 | $170,301,000 | $176,949,000 | $140,288,000 | $128,238,000 | $111,119,000 | $6,824,000 |
| Auryxia | $181,542,000 | $152,180,000 | $170,301,000 | — | — | — | — | — |
| Vafseo | $45,790,000 | $0 | $0 | — | — | — | — | — |
| License Collaboration and Other Revenue | $8,864,000 | $8,000,000 | $24,322,000 | $115,535,000 | $71,362,000 | $166,406,000 | $223,882,000 | $200,918,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $23,499,000 | -$50,472,000 | -$46,256,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | 9.9% | -31.5% | -23.8% |
Key facts
CIK
1517022
CUSIP
00972D105
13F (30d)
53 filings
53 filers
Visit website
Investor relations